BioMenace Remastered

Rigel Gameworks · 2025 · $14.99 · Action · deal grade B

Measured on 2026-10-01 15:51 UTC, 4 days ago. The whole catalog is re-measured daily; a game that just launched can move fast between passes.

• Estimated net residual revenue: $597 to $895 per month
• Opportunity: $970 per month at x1.30 dormancy
• Estimated lifetime owners: 7.4k
• 99% positive across 186 reviews · 5.9 reviews/month

Why it's flagged

• Developer active, last post 0 months ago
• Store page localized in only 1 language(s)

Analyst notes (AI-assisted)

Note written 2026-09-05; the live figures above take precedence over any numbers in it.

BioMenace Remastered is a 2025 remaster of a 1993 DOS-era side-scrolling shooter-platformer, featuring redrawn pixel art, a new fourth episode, and modernized weapon mechanics.

This is a quiet but solid performer in the retro-platformer niche, posting near-perfect sentiment and steady organic traction six months post-launch. The developer remains active, the community is engaged, and residual revenue sits at a healthy mid-four-figure monthly baseline. The game is not a mainstream hit, but it occupies a specific, defensible position in the indie retro catalog and may warrant acquisition or co-publishing support if the buyer seeks stable dormant-title revenue with low operational overhead. Most realistic play: acquisition.

• Risk: Retro DOS-platformer appeal is niche; growth ceiling is likely constrained by audience size and low mainstream awareness despite positive YouTuber signal (Civvie 11).
• Risk: No prior discount history (-1 months since last promotion) suggests either deliberate pricing strategy or lack of retail exposure; revival via sales campaigns is untested.
• Risk: Localization gap to German (13.8%) suggests opportunity cost in European markets; single language on store listing may limit accessibility.

This case as Markdown · Estimates carry ±30-50% error per title.